The ACST chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACST chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ACST stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ACST Detailed Price Forecast - CNN Money||View ACST Detailed Summary - Google Finance|
|View ACST Detailed Summary - Yahoo! Finance||View ACST Stock Research & Analysis - Zacks.com|
|View ACST Trends & Analysis - Trade-Ideas||View ACST Major Holders - Barrons|
|View ACST Call Transcripts - NASDAQ||View ACST Breaking News & Analysis - Seeking Alpha|
|View ACST Annual Report - CompanySpotlight.com||View ACST OTC Short Report - OTCShortReport.com|
|View ACST Fundamentals - TradeKing||View ACST SEC Filings - Bar Chart|
|View Historical Prices for ACST - The WSJ||View Performance/Total Return for ACST - Morningstar|
|View the Analyst Estimates for ACST - MarketWatch||View the Earnings History for ACST - CNBC|
|View the ACST Earnings - StockMarketWatch||View ACST Buy or Sell Recommendations - MacroAxis|
|View the ACST Bullish Patterns - American Bulls||View ACST Short Pain Metrics - ShortPainBot.com|
|View ACST Stock Mentions - StockTwits||View ACST Stock Mentions - PennyStockTweets|
|View ACST Stock Mentions - Twitter||View ACST Investment Forum News - Investor Hub|
|View ACST Stock Mentions - Yahoo! Message Board||View ACST Stock Mentions - Seeking Alpha|
|View Insider Transactions for ACST - SECform4.com||View Insider Transactions for ACST - Insider Cow|
|View ACST Major Holdings Summary - CNBC||View Insider Disclosure for ACST - OTC Markets|
|View Insider Transactions for ACST - Yahoo! Finance||View Institutional Holdings for ACST - NASDAQ|
|View ACST Stock Insight & Charts - FinViz.com||View ACST Investment Charts - StockCharts.com|
|View ACST Stock Overview & Charts - BarChart||View ACST User Generated Charts - Trading View|
Acasti Pharma to Present at the 11th Annual LD Micro Main Event
Posted on Tuesday November 27, 2018
Laval, Québec / ACCESSWIRE / November 27, 2018 / Acasti Pharma Inc. (ACST) (ACST) (the "Company" or "Acasti Pharma"), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the Company is scheduled to present at the 11th annual LD Micro Main Event on Wednesday, December 5 at 3:00 PM PST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Jan D'Alvise, President and Chief Executive Office, will be presenting, as well as meeting with investors.
Acasti: Fiscal 2Q Earnings Snapshot
Posted on Wednesday November 14, 2018
On a per-share basis, the Laval, Quebec-based company said it had a loss of 47 cents. Losses, adjusted for non-recurring costs and amortization costs, came to 19 cents per share. The company's shares closed ...
Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019
Posted on Wednesday November 14, 2018
LAVAL, Québec, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the fiscal second quarter ended September 30, 2018. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “Following our recent capital raises in the U.S. and Canada, I am pleased to report as of November 1, we had over $52 million of cash on hand.
Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
Posted on Wednesday November 07, 2018
Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST) (the “Company” or “Acasti”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will host a conference call at 11:00 AM Eastern Time on Wednesday, November 14, 2018 to discuss the Company’s financial results for the fiscal second quarter ended September 30, 2018, as well as the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 877-407-8031 for U.S. callers or +1 201-689-8031 for international callers, or on the Company’s News and Investors section of the website: https://www.acastipharma.com/investors/.